1,4-二苄基哌嗪-2-羧酸乙酯 | 72351-59-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1,4-二苄基哌嗪-2-羧酸乙酯
• 中文别名: 1,4-二苄基吡嗪-2-甲酸乙酯
• 英文名称: ethyl 1,4-dibenzylpiperazin-2-carboxylate
• 英文别名: 1,4-bis(phenylmethyl)-2-piperazinecarboxylic acid,ethyl ester；1,4-dibenzylpiperazine-2-carboxylic acid ethyl ester；ethyl 1,4-dibenzyl-2-piperazinecarboxylate；ethyl 1,4-dibenzylpiperazine-2-carboxylate；1,4-dibenzyl-2-ethoxycarbonylpiperazine；1,4-Dibenzyl-piperazine-2-carboxylic acid ethyl ester
• CAS: 72351-59-8
• 化学式: C₂₁H₂₆N₂O₂
• mdl: MFCD00126366
• 分子量: 338.45
• InChiKey: KKXWTUYDLQVOOO-UHFFFAOYSA-N

物化性质

• 沸点：
  200 °C
• 密度：
  1.130±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090

SDS

Name:	Ethyl 1 4-dibenzylpiperazine-2-carboxylate 97% Material Safety Data Sheet
Synonym:	N,N'-1,4-Dibenzyl-2-ethoxycarbonyl piperazin
CAS:	72351-59-8

Section 1 - Chemical Product MSDS Name:Ethyl 1 4-dibenzylpiperazine-2-carboxylate 97% Material Safety Data Sheet
Synonym:N,N'-1,4-Dibenzyl-2-ethoxycarbonyl piperazin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
72351-59-8	Ethyl 1,4-dibenzylpiperazine-2-carboxy	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 72351-59-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: orange
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 204 - 208 deg C @1.5mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C21H26N2O2
Molecular Weight: 338.45

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide, ammonia.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 72351-59-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 1,4-dibenzylpiperazine-2-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 72351-59-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 72351-59-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 72351-59-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,4-二苄基哌嗪-2-羧酸乙酯 在 palladium 10% on activated carbon 、 甲酸铵 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以86%的产率得到2-哌嗪甲酸乙酯
  参考文献：
  名称：

  1,4-二氮杂双环[3.3.1]壬南-6-酮的合成

  摘要：

  1,4-二氮杂双环[3.3.1]壬烷（氮杂吗啡）代表构象受限的哌嗪衍生物。在这里，我们报告了六步合成苄基和烯丙基取代的双环酮3a和3b的过程，它们代表了构象受限受体配体合成的有趣结构单元。合成的关键步骤是将丙烯酸乙酯区域选择性地添加到哌嗪8中，六甲基二硅叠氮化钠诱导的二酯10的Dieckmann环化，以及用稀HCl使烯醇酯11脱羧。仅当苄基（10a）或烯丙基部分（10b）时，完整序列才成功由于甲苯磺酰基衍生物10f不能给出狄克曼环化产物，并且酰基衍生物11c和11d的脱羧作用失败，所以将其连接到N-1上。

  DOI：

  10.1071/ch09206
• 作为产物：
  描述：

  苯甲醛 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 甲苯 为溶剂， 生成 1,4-二苄基哌嗪-2-羧酸乙酯
  参考文献：
  名称：

  设计，合成和评价吡咯嗪衍生物作为二环酪氨酸（cYY）模拟物的结核分枝杆菌

  摘要：

  三个系列唑哌嗪衍生物的模拟dicyclotyrosine（CYY），必需的天然底物的结核分枝杆菌的细胞色素P450 CYP121A1，制备并评价针对结合亲和力和抑制活性（MIC）的结核分枝杆菌。系列A替代了一个酚基团CYY的与C3-咪唑部分，系列B包括在系列A咪唑之前的烃链上的酮基，而C系列探索用CH替换CYY的哌啶酮环的酮基2 -咪唑或CH 2-三唑部分，以增强与CYP121A1血红素的结合相互作用。除B 10a系列外，该系列对CYP121A1显示中等至弱II型结合亲和力，其中显示了混合的I型绑定。在这三个系列中，系列C咪唑衍生物显示出对结核分枝杆菌的最佳抑制作用，尽管抑制作用适中（17d MIC = 12.5μg/ mL，17a 50μg/ mL）。确定了与系列A化合物6a和6b结合的CYP121A1的晶体结构，这些化合物显示，咪唑基团位于血红素铁的正上方，并且两个化合物的血红素铁和咪唑氮之间的键合距离为2

  DOI：

  10.1016/j.bmc.2017.11.030

文献信息

• 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
  申请人：Schering Corporation

  公开号：US20040106794A1

  公开（公告）日：2004-06-03

  There are disclosed compounds of the formula 1 or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

  这里公开了用于治疗诸如急性和慢性炎症性疾病以及癌症的趋化因子介导疾病的公式1化合物或其药用可接受的盐或溶剂。
• 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
  申请人：Schering Corporation

  公开号：US20040220194A1

  公开（公告）日：2004-11-04

  Compounds having the structural formula I 1 or a pharmaceutically acceptable salt thereof, wherein R is 2 R 1 , R 2 , R 3 , R 4 and R 5 are H, alkyl or alkoxyalkyl; R 6 is H, alkyl, hydroxyalkyl or —CH 2 F; R 7 , R 8 and R 9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF 3 ; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

  具有结构式I或其药用可接受盐的化合物，其中R是R1，R2，R3，R4和R5为H，烷基或烷氧基烷基；R6为H，烷基，羟基烷基或—CH2F；R7，R8和R9为H，烷基，烷氧基，烷硫基，烷氧基烷基，卤素或—CF3；以及Z是可选择地取代的芳基，杂环芳基或杂环芳基烷基。还公开了化合物I的应用于治疗中枢神经系统疾病，特别是帕金森病，单独或与其他治疗帕金森病的药剂联合使用，以及包含它们的药物组合物。
• Quinoline derivatives as neurokinin receptor antagonists
  申请人：Carling William Robert

  公开号：US20090054440A1

  公开（公告）日：2009-02-26

  The present invention relates to substituted quinoline hydrazides of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, Y and Z are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.

  本发明涉及式(I)所示的取代喹啉酰肼：其中R1、R2、R3、R4、R5、X、Y和Z在此定义，包含它们的药物组合物及其在治疗由神经激肽-2和/或神经激肽-3 (NK-3)受体介导的疾病中的用途。因此，这些化合物可用于治疗方法，以抑制和治疗这些疾病。
• [EN] THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS<br/>[FR] THIADIAZOLEDIOXYDES ET THIADIAZOLEOXIDES CONVENANT COMME LIGANDS DES RECEPTEURS DES CXC- ET CC-CHIMIOKINES
  申请人：PHARMACOPEIA INC

  公开号：WO2004033440A1

  公开（公告）日：2004-04-22

  Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

  披露了公式（IA）的新颖化合物以及其中医药可接受的盐和溶剂化物。包含取代基A的基团示例包括杂芳基、芳基、杂环烷基、环烷基、芳基、炔基、烯基、氨基烷基、烷基或氨基。包含取代基B的基团示例包括芳基和杂芳基。还披露了一种治疗趋化因子介导的疾病的方法，例如，癌症、血管生成、血管生成性眼病、肺病、多发性硬化症、类风湿性关节炎、骨关节炎、中风和心脏再灌注损伤、急性疼痛、急性和慢性炎症性疼痛，以及使用公式（IA）的化合物的神经性疼痛。
• [EN] ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS<br/>[FR] DIOXYDES D'ISOTHIAZOLE EN TANT QUE LIGANDS DU RECEPTEUR DE LA CHIMIOKINE CXC ET CC
  申请人：SCHERING CORP

  公开号：WO2005068460A1

  公开（公告）日：2005-07-28

  Disclosed are novel compounds of the formula (IA): and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

  公开了公式(IA)的新化合物：以及它们的药物可接受的盐和溶剂化物。D和E是不同的基团，其中一个是N，另一个是CR50。包含取代基A的基团示例包括杂芳基、芳基、杂环烷基、环烷基、芳基、炔基、烯基、氨基烷基、烷基或氨基。包含取代基B的基团示例包括芳基和杂芳基。还公开了一种治疗趋化因子介导的疾病的方法，例如，癌症、血管生成、血管生成性眼病、肺病、多发性硬化症、类风湿性关节炎、骨关节炎、中风和心肌再灌注损伤，疼痛(例如，急性疼痛、急性和慢性炎症性疼痛、神经性疼痛)使用公式IA的化合物。